Collegium Pharma (COLL) Prices 5M Share Stock Offering for Proceeds of $80M
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock offered in the public offering on the same terms and conditions. The gross proceeds of this offering are expected to be $80 million, excluding underwriters’ discounts and commissions and any exercise of the underwriters’ option to purchase an additional 750,000 shares of common stock. If the underwriters’ option is exercised in full, gross proceeds will be $92 million, excluding underwriters’ discounts and commissions. The offering is expected to close on October 31, 2016, subject to customary closing conditions.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers. William Blair & Company, L.L.C. and Needham & Company, LLC are acting as co-lead managers and Janney Montgomery Scott LLC is acting as co-manager in this offering.
Collegium intends to use the net proceeds from this offering for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.
The securities described above are being offered by Collegium pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange Commission (“SEC”). Before you invest, you should read the base prospectus in the registration statement and related prospectus supplement that Collegium has filed with the SEC for more complete information about Collegium and this offering. The prospectus supplement and accompanying base prospectus are available for free by visiting EDGAR on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and accompanying base prospectus, when available, may also be obtained by contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at firstname.lastname@example.org.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caterpillar (CAT) Offers FY17 Guidance Update at Credit Suisse Conference
- Amyris (AMRS) Files to sell $10M Convertible Note
- UPDATE: Global Eagle Entertainment (ENT) to Obtain New Credit Facilities; Company in Discussions to Acquire Related Business, Satellite Transponders
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesPiper Jaffray, William Blair, Jefferies & Co, Needham & Company, Janney Montgomery Scott, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!